Sunshine Biopharma entered into an At-The-Market Issuance Sales Agreement to raise up to $4.0 million by selling common stock through Aegis Capital as exclusive sales agent. Sales may be made from time to time on the Nasdaq Capital Market or other trading venues, with Aegis earning a 3.0% commission on gross proceeds plus expenses. Neither party is obligated to sell or buy shares, and timing and pricing will depend on market conditions. The program is intended to provide flexible access to capital to support the company’s needs.
Agreement details:
- Agreement type: At-the-market issuance sales agreement for common stock
- Counterparty: Aegis Capital
- Signed / Effective: Jul 20 2026 / Jul 20 2026
- Duration / Termination: At will
- Reason: Raise capital and enhance liquidity
Original SEC Filing:
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.